Go to:
Logótipo
Você está em: Start > Publications > View > Neuropathic Pain After Breast Cancer Treatment: Characterization and Risk Factors
Map of Premises
Principal
Publication

Neuropathic Pain After Breast Cancer Treatment: Characterization and Risk Factors

Title
Neuropathic Pain After Breast Cancer Treatment: Characterization and Risk Factors
Type
Article in International Scientific Journal
Year
2017
Authors
Fontes, F
(Author)
Other
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page View ORCID page
Sonin, T
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Dias, T
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Fragoso, M
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Castro-Lopes J.M.
(Author)
FMUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page View ORCID page
Lunet N
(Author)
FMUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page View ORCID page
Journal
Vol. 54
Pages: 877-888
ISSN: 19395914
Publisher: Elsevier
Other information
Authenticus ID: P-00N-G71
Abstract (EN): Context. Neuropathic pain (NP) may be an important contributor to the morbidity burden of breast cancer. Objectives. We aimed to quantify the incidence of NP in the first year after diagnosis of breast cancer and to identify its main determinants. Methods. We performed a prospective cohort study including 506 patients with incident breast cancer, recruited at the Portuguese Institute of Oncology of Porto, and followed for one year; patients with incident NP were additionally evaluated when this condition was diagnosed and after six months, to identify chronic NP. Results. During the first year, 156 patients were diagnosed with NP (30.8%, 95% CI 27.0-35.0). Anxiety (relative risk [RR] 1.50; 95% CI 1.06-2.13), arm symptoms (RR 1.44; 95% CI 1.02-2.05), cancer Stage III/IV (RR 2.47; 95% CI 1.66-3.66), breast-conserving surgery with axillary lymph node dissection (RR 3.13; 95% CI 1.51-6.48), mastectomy with axillary lymph node dissection (RR 2.52; 95% CI 1.25-5.11), and damaging of the intercostobrachial nerve (RR 2.05; 95% CI 1.25-3.37) were predictors of a higher risk of NP. A total of 97 patients (62.2%, 95% CI 54.4-69.4) diagnosed with NP remained symptomatic after six months. Conclusion. NP and chronic NP were frequent in this population, being associated with anxiety and arm symptoms before breast cancer treatments and type of surgical management. These results highlight the need for monitoring the occurrence of this neurologic side effect of treatments and to develop strategies for reducing the morbidity burden of breast cancer.
Language: English
Type (Professor's evaluation): Scientific
No. of pages: 12
Documents
We could not find any documents associated to the publication.
Related Publications

Of the same authors

Chemotherapy-induced peripheral neuropathy after neoadjuvant or adjuvant treatment of breast cancer: a prospective cohort study (2016)
Article in International Scientific Journal
Ferreira S; Fontes, F; Sonin, T; Dias, T; Fragoso, M; Castro-Lopes J.M.; Lunet N

Of the same journal

Psychosocial predictors of health status in fibromyalgia: a comparative study with rheumatoid arthritis (2009)
Article in International Scientific Journal
Paula Oliveira; Maria Emília Costa
Recommend this page Top
Copyright 1996-2025 © Faculdade de Medicina Dentária da Universidade do Porto  I Terms and Conditions  I Acessibility  I Index A-Z
Page created on: 2025-08-08 at 23:27:17 | Privacy Policy | Personal Data Protection Policy | Whistleblowing | Electronic Yellow Book